IntelGenx Corp. and Circ Pharma Ltd announced today a partnership to develop and commercialise a novel drug for the treatment of hyperlipidemia.

January 19, 2009

Saint Laurent, Quebec, and Dublin, Ireland - Jan. 19, 2009 - IntelGenx Corporation (OTCBB:IGXT, TSXV:IGX)("IntelGenx") and Circ Pharma (“Circ”) today announced a partnership in which IntelGenx will  formulate, manufacture and supply to Circ, and Circ will develop and commercialise, a novel drug product for the treatment of hyperlipidemia.  Under the terms of the agreement, Circ Pharma will fund the development of the product and IntelGenx will receive royalties from the product’s sales.  IntelGenx will use its proprietary VersaTab™ technology to formulate the product.  

This is the first product in a series of Circ Pharma’s controlled release lipid lowering agents specifically designed to target the absorption of drug in order to reduce the effective dose and potentially lower the side effects.  The product is expected to reach the market in 2012.  The lipid lowering market had over $30 billion in worldwide sales during 2008.

 “We are very pleased about this collaboration with Circ Pharma.  It is another testament to our drug development capabilities.  We are looking forward to a productive and successful relationship with Circ Pharma.” said Dr. Horst Zerbe, President and CEO of IntelGenx Corp.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the company at

Circ Pharma is a specialty pharmaceutical product development company, based in Ireland, whose mission is to develop differentiated novel formulations of products based on existing drugs that provide incremental patient benefit. Circ Pharma has a strong intellectual property portfolio and technology in the areas of targeted and chronotherapeutic drug delivery with pipeline of novel product opportunities in a number of indications including cardiovascular and CNS/pain indications.


This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

The TSX and OTCBB have neither approved nor disapproved of the information contained herein.


IntelGenx Corp.
Dr. Horst G. Zerbe,
President and CEO
T: +1 514-331-7440 (ext. 201)
F: +1 514-331-0436


Circ Pharma Ltd.
Margot Foynes
Chief Technical Officer
T: +353-1-6344186
F: +353-1-6344188